NEW YORK (GenomeWeb News) – AdvanDx, a provider of molecular diagnostics for pathogen identification, said today that it has closed a $12 million Series B-1 financing round.

The financing will go toward expansion of the Woburn, Mass.-based company's product offerings and its sales and marketing operations in the US and abroad, it said.

Merck Global Health Innovation Fund led the round and was joined by existing investors SLS Ventures and LD Pensions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.